Employee-Paid

Employer costs for GLP-1 agonists and similar drugs could end up averaging $3.17 to $22.88 per enrollee per month.

Employers here may have a harder time bargaining with the providers and policymakers.

Stop-loss issuers have been talking for more than a year about seeing a broad, powerful surge in claims.

They are also worried about hospital prices and states nibbling away at ERISA preemption.

One thing a big new batch of Census data shows is where employer plans still have some clout.

Advisors should view this as an opportunity to deliver thoughtful retirement income strategies to clients and help them resist common behavioral tendencies.